ArticleResearch square2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
In preclinical models, PCSK9 mediates cancer immunotherapy resistance and may serve as a novel immuno-inhibitory target. Herein, we report the results from a multi-center, single arm, phase II study evaluating the clinical activity and safety of the PCSK9 inhibitor alirocumab, in combination with the anti-PD1 antibody cemiplimab, in non-small cell lung cancer (NSCLC) patients with disease progression after previous immune checkpoint blockade. The primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response (DOR), disease control rate (DCR) and safety, and an exploratory objective was to analyze potential biomarkers of response. Sixty patients were enrolled, and 58 were evaluable for ORR. The ORR was 14.78% (90% CI, 5.30, 25.43), the median PFS was 2.5 months (95% CI, 1.5-3), and the median OS was 7.3 months (95% CI, 5.4 - 12.3). The most common treatment related adverse events (all grades) were anemia and fatigue. Grade 3 adverse events occurred in seven (12%) patients and were anemia, Guillain-Barre Syndrome and elevated amino transferase. There were no treated related adverse events of grade 4 or greater in the study population. Biomarker analysis identified superior outcomes in NSCLC harboring PIK3CA, PTEN, or AKT1 alterations. The ORR in patients with PIK3CA, PTEN, or AKT1 alterations (n=17) was 29.4% (95% CI, 10.3% - 56.0%). No objective responses were observed in the absence of PIK3CA, PTEN or AKT1 alterations (n=39). The presence of PIK3CA, PTEN or AKT1 alterations was significantly associated with response, p 0.0032 (two-sided, Fisher's exact test). Further translational studies revealed the impact of PIK3CA, PTEN or AKT1 alterations on intratumoral PCSK9, providing a biological rationale for the pattern of response and clinical benefit. These findings provide clinical proof-of-principle that PCSK9 inhibition can overcome immunotherapy resistance in a subset of patients and suggest that PIK3CA/PTEN/AKT1 pathway plays a significant role in PCSK9 mediated immune evasion and could be a biomarker of response. These findings warrant further investigation in larger confirmatory studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.